Amgen's transformation and process improvement initiatives are enabling the company to reallocate resources to fund many of its innovative pipeline and growth opportunities that deliver value to patients and stockholders. The transformation includes a restructuring plan that will result in pre-tax accounting charges in the range of $800 million to $900 million, with savings realized from these efforts being reinvested in product launches, clinical programs, and external business development. The company has committed to a more agile and efficient operating model, which is essential for long-term growth. Amgen's strategy focuses on developing innovative medicines in therapeutic areas that meet significant unmet medical needs, leveraging its expertise to improve health outcomes. The company has invested in next-generation biomanufacturing to reduce the scale and cost of making biologics while ensuring a reliable, high-quality, compliant supply of medicines. Additionally, Amgen's ongoing transformation is aimed at enhancing operational efficiency and improving its ability to respond to market dynamics and competitive pressures. The company has also emphasized the importance of mobilizing and deploying IT-based resources in combination with leveraging other resources and capabilities to transform into a competitive force. The focus on information management capability is critical, as it involves providing data and information to users with appropriate levels of accuracy, timeliness, reliability, security, confidentiality, connectivity, and access, tailored to changing business needs. Amgen's commitment to innovation is reflected in its investments in external early-stage innovation to augment internal research efforts, which is crucial for maintaining competitive advantage. The company recognizes that its long-term success depends on its ability to discover, develop, and commercialize innovative products while navigating increasing regulatory scrutiny and competitive pressures. The transformation initiatives are designed to establish a foundation for longer-term growth, enabling Amgen to approach the development of new medicines with greater understanding, speed, and confidence. The company is well-positioned to address the challenges and opportunities in the coming year, with a focus on executing its strategy and delivering results that align with its organizational goals. Amgen's commitment to enhancing its IT capabilities and operational flexibility is vital in responding to the evolving business environment and ensuring the effective management of its resources.